Siemens S46 User Manual page 105

People who must conduct extended conversations in their cars every day
could switch to a type of mobile phone that places more distance between
their bodies and the source of the RF , since the exposure level drops off
dramatically with distance. For example, they could switch to:
• a mobile phone in which the antenna is located outside the vehicle,
• a hand-held phone with a built-in antenna connected to a different antenna
mounted on the outside of the car or built into a separate package, or
• a headset with a remote antenna to a mobile phone carried at the waist.
Where can I find additional information?
For additional information, see the following websites:
• Federal Communications Commission (FCC) RF Safety Program (select
"Information on Human Exposure to RF Fields from Cellular and PCS Radio
Transmitters"): http://www.fcc.gov/oet/rfsafety.
• World Health Organization (WHO) International Commission on Non-
Ionizing Radiation Protection (select Qs & As): http://www.who.int/emf
• United Kingdom, National Radiological Protection Board: http://
www.nrpb.org.uk
• Cellular Telecommunications Industry Association (CTIA): http://
www.wow-com.com
• U.S. Food and Drug Administration (FDA) Center for devices and
Radiological Health: Http://www.fda.gov/cdhr/consumer/
1
Muscat et al. Epidemiological Study of Cellular Telephone Use and
Malignant Brain Tumors. In: State of the Science Symposium; 1999 June 20;
Long Beach, California.
2
Tice et al. Tests of mobile phone signals for activity in genotoxicity and other
laboratory assays. In: Annual Meeting of the Environmental Mutagen Society;
March 29, 1999, Washington, DC; and personal communication, unpublished
results.
3
Preece, AW, Iwi, G, Davies-Smith, A, Wesnes, K, Butler, S, Lim, E, and
Varey, A. Effect of a 915- MHz simulated mobile phone signal on cognitive
function in man. Int. J. Radiat. Biol., April 8, 1999.
4
Hardell, L, Nasman, A, Pahlson, A, Hallquist, A and Mild, KH. Use of cellular
telephones and the risk for brain tumors; a case-control study. Int. J. Oncol,
15: 113-116, 1999.
U.S. FDA
101